Announcements Trials

Browse Landscape

Phase

Phase 2 10 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Propofol 9 Sevoflurane 7 Rituximab 7 Specimen Handling 6 Magnetic Resonance Spectroscopy 6 Dexamethasone 6 Trastuzumab 5 Enoxaparin 5 Bevacizumab 5 Nivolumab 4 Carboplatin 4 Capecitabine 4 Bupivacaine 4 trametinib 3 pirtobrutinib 3 pembrolizumab 3 dabrafenib 3 atezolizumab 3 apixaban 3 Lenalidomide 3 Indocyanine Green 3 Gemcitabine 3 Docetaxel 3 Cyclophosphamide 3 zanubrutinib 2 venetoclax 2 trastuzumab deruxtecan 2 ribociclib 2 polyethylene glycol 3350 2 pertuzumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Recruiting × surufatinib × Clear all

NCT07272512 2025-12-19

ZSPAC-17

Shanghai Zhongshan Hospital

Phase 4 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡